Healthcare resource use and costs of varicella and its complications: A systematic literature review

References

• World Health Organization (WHO). Varicella: vaccine preventable diseases surveillance standards. Published 2018. https://www.who.int/publications/m/item/vaccine-preventable-diseases-surveillance-standards-varicella.
   Google Scholar
• Lee T, Suh J, Choi JK, Lee J, Park SH. Estimating the basic reproductive number of varicella in South Korea incorporating social contact patterns and seroprevalence. Hum Vaccines Immunother. 2021;17(8):2488–13. doi:10.1080/21645515.2021.1898917.
   PubMed Web of Science ®Google Scholar
• Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I, Rota MC, de Melker H, Mossong J, Slacikova M, et al. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine. 2007;25(45):7866–72. doi:10.1016/J.VACCINE.2007.07.036.
   PubMed Web of Science ®Google Scholar
• Bollaerts K, Riera-Montes M, Heininger U, Hens N, Souverain A, Verstraeten T, Hartwig S. A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data. Epidemiol Infect. 2017;145(13):2666–77. doi:10.1017/S0950268817001546.
   PubMed Web of Science ®Google Scholar
• Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PG, Oxman MN, Seward JF. Varicella zoster virus infection. Nat Rev Dis Prim. 2015;1(1):1–41. doi:10.1038/nrdp.2015.16.
   Web of Science ®Google Scholar
• Banz K, Iseli A, Aebi C, Brunner M, Schmutz AM, Heininger U. Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccin. 2009;5(12):847–57. doi:10.4161/hv.9898.
   PubMed Web of Science ®Google Scholar
• Riera-Montes M, Bollaerts K, Heininger U, Hens N, Gabutti G, Gil A, Nozad B, Mirinaviciute G, Flem E, Souverain A, et al. Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization. BMC Infect Dis. 2017;17(1):1–16. doi:10.1186/s12879-017-2445-2.
   PubMedGoogle Scholar
• Pawaskar M, Méroc E, Samant S, Flem E, Bencina G, Riera-Montes M, Heininger U. Economic burden of varicella in Europe in the absence of universal varicella vaccination. BMC Public Health. 2021;21(1):1–11. Published online. doi:10.1186/s12889-021-12343-x.
   PubMed Web of Science ®Google Scholar
• Arlant LHF, Garcia MCP, Avila Aguero ML, Cashat M, Parellada CI, Wolfson LJ. Burden of varicella in Latin America and the Caribbean: findings from a systematic literature review. BMC Public Health. 2019;19(1):1–18. doi:10.1186/s12889-019-6795-0.
   PubMedGoogle Scholar
• Damm O, Witte J, Wetzka S, Prosser C, Braun S, Welte R, Greiner W. Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review. Int J Public Health. 2016;61(7):847–60. doi:10.1007/s00038-016-0842-8.
   PubMed Web of Science ®Google Scholar
• Bozzola E, Bozzola M, Krzysztofiak A, Tozzi AE, Hachem M, El Villani A. Varicella skin complications in childhood: a case series and a systematic review of the literature. Int J Mol Sci. 2016;17(5):688. doi:10.3390/ijms17050688.
   PubMed Web of Science ®Google Scholar
• PRISMA. PRISMA, transparent reporting of systematic reviews and meta-analyses. Published 2020. http://www.prisma-statement.org/.
   Google Scholar
• Hong Q, Fàbregues S, Bartlett G, Boardman F., Cargo M, Dagenais P, Gagnon MP, Griffiths F, Nicolau B, O’Cathain A, et al. The mixed methods appraisal tool (MMAT) version 2018 for information professionals and researchers. Educ Inf. 2018;34(4):285–91. doi:10.3233/EFI-180221.
   Web of Science ®Google Scholar
• ISPOR. Consolidated health economic evaluation reporting standards (CHEERS) 2022 resources. Published 2022. https://www.ispor.org/heor-resources/good-practices/cheers.
   Google Scholar
• Bernal JL, Hobbelen P, Amirthalingam G. Burden of varicella complications in secondary care, England, 2004 to 2017. Eurosurveillance. 2019;24(42). doi:10.2807/1560-7917.ES.2019.24.42.1900233.
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Chickenpox (varicella). Published 2021. https://www.cdc.gov/chickenpox/about/complications.html
   Google Scholar
• OECD. Health care prices and purchasing power parities. Published 2020. https://www.oecd.org/health/health-purchasing-power-parities.htm
   Google Scholar
• FRED EDSLF. Consumer price index for all urban consumers: medical care in U.S. Published 2020. https://fred.stlouisfed.org/series/CPIMEDSL
   Google Scholar
• Wutzler P, Neiss A, Banz K, Goertz A, Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med Microbiol Immunol. 2002;191(2):89–96. doi:10.1007/s00430-002-0123-4.
   PubMed Web of Science ®Google Scholar
• Wagenpfeil S, Neiss A, Banz K, Wutzler P. Empirical data on the varicella situation in Germany for vaccination decisions. Clin Microbiol Infect. 2004;10(5):425–30. doi:10.1111/j.1469-0691.2004.00853.x.
   PubMed Web of Science ®Google Scholar
• Haugnes H, Flem E, Wisløff T. Healthcare costs associated with varicella and herpes zoster in Norway. Vaccine. 2019;37(29):3779–84. doi:10.1016/j.vaccine.2019.05.063.
   PubMed Web of Science ®Google Scholar
• Giglio N, Monsanto H, Rampakakis E, Yang HK, Kuter BJ, Wolfson LJ. Economic burden of varicella in children 1–12 years of age in Argentina, 2009–2014. J Med Econ. 2018;21(4):416–24. doi:10.1080/13696998.2018.1431919.
   PubMed Web of Science ®Google Scholar
• Wolfson LJ, Castillo ME, Giglio N, Meszner Z, Molnar Z, Vazquez M, Wysocki J, Altland A, Kuter BJ, Rickard J, et al. Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe. Hum Vaccines Immunother. 2019;15(4):932–41. doi:10.1080/21645515.2018.1559687.
   PubMed Web of Science ®Google Scholar
• Bilcke J, Christiaan M, Ogunjimi B, van Hoek AJ, Lejeune O, Callens M, Vancorenland S, Van Kerschaver E, Callaert K, Hens N, et al. Cost-utility of Vaccination against Chickenpox in Children and against Herpes Zoster in Elderly in Belgium. Brussels: Health Technology Assessment (HTA), Belgian Health Care Knowledge Centre (KCE); 2010. KCE Reports 151.
   Google Scholar
• Valentim J, Sartori AMC, de Soárez PC, Amaku M, Azevedo RS, Novaes HMD, de Soárez PC. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine. 2008;26(49):6281–91. doi:10.1016/j.vaccine.2008.07.021.
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. The cost-effectiveness of varicella vaccination in Canada. Vaccine. 2002;20(7–8):1113–25. doi:10.1016/S0264-410X(01)00437-6.
   PubMed Web of Science ®Google Scholar
• De Wals P, Blackburn M, Guay M, Bravo G, Blanchette D, Douville-Fradet M. Burden of chickenpox on families: a study in Quebec. Can J Infect Dis. 2001;12(1):27–32. doi:10.1155/2001/361070.
   PubMedGoogle Scholar
• Littlewood KJ, Ouwens MJNM, Sauboin C, Tehard B, Alain S, Denis F. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster. Clin Ther. 2015;37(4):830–41.e7. doi:10.1016/j.clinthera.2015.01.006.
   PubMed Web of Science ®Google Scholar
• Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, Wutzler P. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine. 2003;21(11–12):1256–67. doi:10.1016/S0264-410X(02)00431-0.
   PubMed Web of Science ®Google Scholar
• Banz K, Wagenpfeil S, Neiss A, Hammerschmidt T, Wutzler P. The burden of varicella in Germany: potential risks and economic impact. Eur J Heal Econ. 2004;5(1):46–53. doi:10.1007/s10198-003-0200-7.
   PubMedGoogle Scholar
• Meszner Z, Molnar Z, Rampakakis E, Yang HK, Kuter BJ, Wolfson LJ. Economic burden of varicella in children 1-12 years of age in Hungary, 2011-2015. BMC Infect Dis. 2017;17(1):1–11. doi:10.1186/s12879-017-2575-6.
   PubMedGoogle Scholar
• Thiry N, Beutels P, Tancredi F, Romanò L, Zanetti A, Bonanni P, Gabutti G, Damme PV. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine. 2004;22(27–28):3546–62. doi:10.1016/j.vaccine.2004.03.043.
   PubMed Web of Science ®Google Scholar
• Coudeville L, Brunot A, Giaquinto C, Lucioni C, Dervaux B. Varicella vaccination in Italy: an economic evaluation of different scenarios. Pharmacoeconomics. 2004;22(13):839–55. doi:10.2165/00019053-200422130-00003.
   PubMed Web of Science ®Google Scholar
• Melegaro A, Marziano V, Del Fava E, Poletti P, Tirani M, Rizzo C, Merler S. The impact of demographic changes, exogenous boosting and new vaccination policies on varicella and herpes zoster in Italy: a modelling and cost-effectiveness study. BMC Med. 2018;16(1):1–13. doi:10.1186/s12916-018-1094-7.
   Google Scholar
• Wolleswinkel-van den Bosch JH, Speets AM, Rümke HC, Gumbs PD, Fortanier SC. The burden of varicella from a parent’s perspective and its societal impact in the Netherlands: an Internet survey. BMC Infect Dis. 2011;11(1):320. doi:10.1186/1471-2334-11-320.
   PubMedGoogle Scholar
• Boot HJ, de Melker HE, Stolk EA, de Wit GA, Kimman TG. Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine. 2006;24(37–39):6288–99. doi:10.1016/j.vaccine.2006.05.071.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Malecka I, Stryczynska-Kazubska J, Rampakakis E, Kuter B, Wolfson LJ. Varicella in Poland: economic burden in children 1-12 years of age in Poland, 2010-2015. BMC Public Health. 2018;18(1):1–0. doi:10.1186/s12889-018-5298-8.
   Google Scholar
• Blasco GP, Blasco Pérez-Aramendía J. A cost-benefit analysis of varicella vaccination in Aragón. Arch Argent Pediatr. 2017;115(5):432–8. doi:10.5546/aap.2017.432.
   PubMed Web of Science ®Google Scholar
• Díez-Domingo J, Aristegui J, Calbo F, Gonzalez-Hachero J, Moraga F, Peña Guitian J, Ruiz Contreras J, Torrellas A. Epidemiology and economic impact of varicella in immunocompetent children in Spain. A nation-wide study. Vaccine. 2003;21(23):3236–9. doi:10.1016/S0264-410X(03)00264-0.
   PubMed Web of Science ®Google Scholar
• Lenne X, Diez Domingo J, Gil A, Ridao M, Lluch JA, Dervaux B. Economic evaluation of varicella vaccination in Spain-results from a dynamic model. Vaccine. 2006;24(47–48):6980–9. doi:10.1016/j.vaccine.2006.04.051.
   PubMed Web of Science ®Google Scholar
• Wolfson LJ, Daniels VJ, Pillsbury M, Kurugöl Z, Yardimci C, Kyle J, Dinleyici EC. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model. PloS One. 2019;14(8):1–26. doi:10.1371/journal.pone.0220921.
   Web of Science ®Google Scholar
• Turel O, Bakir M, Gonen I, Hatipoglu N, Aydogmus C, Hosaf E, Siraneci R. Children hospitalized for varicella: complications and cost burden. Value Heal Reg Issues. 2013;2(2):226–30. doi:10.1016/j.vhri.2013.05.003.
   PubMedGoogle Scholar
• Van Hoek AJ, Melegaro A, Gay N, Bilcke J, Edmunds WJ. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30(6):1225–34. doi:10.1016/j.vaccine.2011.11.026.
   PubMed Web of Science ®Google Scholar
• Walker JL, Andrews NJ, Mathur R, Smeeth L, Thomas SL. Trends in the burden of varicella in UK general practice. Epidemiol Infect. 2017;145(13):2678–82. doi:10.1017/S0950268817001649.
   PubMed Web of Science ®Google Scholar
• Hsu HC, Lin RS, Tung TH, Chen THH. Cost-benefit analysis of routine childhood vaccination against chickenpox in Taiwan: decision from different perspectives. Vaccine. 2003;21(25–26):3982–7. doi:10.1016/S0264-410X(03)00270-6.
   PubMed Web of Science ®Google Scholar
• Bilcke J, Ogunjimi B, Marais C, De Smet F, Callens M, Callaert K, Van Kerschaver E, Ramet J, Van Damme P, Beutels P, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140(11):2096–109. doi:10.1017/S0950268811002640.
   PubMed Web of Science ®Google Scholar
• Esmaeeli S, Yaghoubi M, Nojomi M. Cost‑effectiveness of varicella vaccination program in Iran. Int J Prev Med. 2017;8(103):1–5. doi:10.4103/ijpvm.IJPVM_295_16.
   PubMedGoogle Scholar
• Zhou F, Ortega-Sanchez IR, Guris D, Shefer A, Lieu T, Seward JF. An economic analysis of the universal varicella vaccination program in the United States. J Infect Dis. 2008;197(Suppl 2):S156–S64. doi:10.1086/522135.
   PubMedGoogle Scholar
• Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos LL, De Serres G. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127(2):305–14. doi:10.1017\S0950268801005921.
   PubMed Web of Science ®Google Scholar
• Vazquez M, Perezbolde C, Monsanto H, Rampakakis E, Altland A, Wolfson LJ, Pastor V. The economic burden of varicella in Mexico. Value Heal. 2018;21:S152. doi:10.1016/j.jval.2018.04.1051.
   Google Scholar
• van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ, van Hoek AJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–67. doi:10.1016/j.vaccine.2008.12.024.
   PubMed Web of Science ®Google Scholar
• Guillen JM, Gil-Prieto R, Alvaro A, Gil A. Burden of adult varicella hospitalizations in Spain (2001-2007). Hum Vaccin. 2010;6(8):659–63. doi:10.4161/hv.6.8.12014.
   PubMed Web of Science ®Google Scholar
• Hobbelen PHF, Stowe J, Amirthalingam G, Miller L, van Hoek AJ. The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. J Infect. 2016;73(3):241–53. doi:10.1016/j.jinf.2016.05.008.
   PubMed Web of Science ®Google Scholar
• Widgren K, Giesecke J, Lindquist L, Tegnell A. The burden of chickenpox disease in Sweden. BMC Infect Dis. 2016;16(1):1–8. doi:10.1186/s12879-016-1957-5.
   PubMedGoogle Scholar
• Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. J Am Med Assoc. 2005;294(7):797–802. doi:10.1001/jama.294.7.797.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Tan HF, Chang CK. Varicella Epidemiology and cost-effectiveness analysis of universal varicella vaccination program in Taiwan. Southeast Asian J Trop Med Public Heal. 2005;36(6):1450–8.
   Google Scholar
• Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. J Pediatr. 1997;130(5):759–65. doi:10.1016/S0022-3476(97)80019-4.
   PubMed Web of Science ®Google Scholar
• Losurdo G, Bertoluzzo L, Canale F, Timitilli A, Bondi E, Castagnola E. Varicella and its complications as cause of hospitalization varicella e sue complicanze come causa. Le Infez Med. 2005;4:229–34.
   Google Scholar
• Macias-Parra M, Rodriguez-Weber MA, Moreno-espinosa S, Ceron-Trujillo B, Ojeda-Diezbarroso K, DeAntonio R, Cortes-Alcala R, Martinez G, Carreño-Manjarrez R, Jiménez-Juárez RN Economic burden of varicella complications in two referral centers in Mexico. Hum Vaccines Immunother. 2018;14(12):2950–4. doi:10.1080/21645515.2018.1504541.
   PubMed Web of Science ®Google Scholar
• Bozzola E, Guolo S, Macchiarulo G, Festa L, Spina G, Krzysztofiak A, Grandin A, Bozzola M, Raponi M, Villani A, et al. Hospitalization for acute cerebellitis in children affected by varicella: how much does it cost? Ital J Pediatr. 2020;46(1):1–4. doi:10.1186/s13052-020-00875-8.
   PubMed Web of Science ®Google Scholar
• Azzari C, Massai C, Poggiolesi C, Indolfi G, Spagnolo G, De Luca M, Gervaso P, de Martino M, Resti M. Cost of varicella-related hospitalisations in an Italian paediatric hospital: comparison with possible vaccination expenses. Curr Med Res Opin. 2007;23(12):2945–54. doi:10.1185/030079907X242610.
   PubMed Web of Science ®Google Scholar
• Büyükcam A, Çelik M, Cengiz M, Ceyhan M, Kara A. The chickenpox complications and financial burden in healthy children and with underlying a comorbidity during the pre vaccine and post vaccine era in a University hospital. Value Heal. 2016;19(7):A406–A7. doi:10.1016/j.jval.2016.09.349.
   Web of Science ®Google Scholar
• Van Lier A, Van Erp J, Donker GA, Van der Maas NAT, Sturkenboom MCJM, De Melker HE. Low varicella-related consultation rate in the Netherlands in primary care data. Vaccine. 2014;32(28):3517–24. doi:10.1016/J.VACCINE.2014.04.034.
   PubMed Web of Science ®Google Scholar
• Herrero-Arias R, Diaz E. A qualitative study on the experiences of southern European immigrant parents navigating the Norwegian healthcare system. Int J Equity Health. 2021;20(1):1–12. doi:10.1186/s12939-021-01384-8.
   PubMed Web of Science ®Google Scholar
• Landsem MM, Magnussen J. The effect of copayments on the utilization of the GP service in Norway. Social Sci Med. 2018;205:99–106. doi:10.1016/J.SOCSCIMED.2018.03.034.
   PubMed Web of Science ®Google Scholar
• Johansson N, Jakobsson N, Svensson M. Effects of primary care cost-sharing among young adults: varying impact across income groups and gender. Eur J Heal Econ. 2019;20(8):1271–80. doi:10.1007/s10198-019-01095-6.
   PubMed Web of Science ®Google Scholar
• Ziebold C, von Kries R, Lang R, Weigl J, Schmitt H. Severe complications of varicella in previously healthy children in Germany: a 1-year survey. Pediatrics. 2001;108(e79):1–6. doi:10.1542/peds.108.5.e79.
   PubMedGoogle Scholar
• Trucchi C, Gabutti G, Rota MC, Bella A. Burden of varicella in Italy, 2001–2010: analysis of data from multiple sources and assessment of universal vaccination impact in three pilot regions. J Med Microbiol. 2015;64(11):1387–94. doi:10.1099/jmm.0.000061.
   PubMedGoogle Scholar
• Iseli A, Aebi C, Banz K, Brunner M, Schmutz AM, Heininger U. Prospective surveillance of varicella-zoster virus infections in an out-patient setting in Switzerland. Hum Vaccin. 2009;5(12):843–6. doi:10.4161/hv.9897.
   PubMed Web of Science ®Google Scholar
• Harpaz R, Van Hoek AJ. Point–counterpoint: the Hope-Simpson hypothesis and its implications regarding an effect of routine varicella vaccination on herpes zoster incidence. JID. 2018;218(2):S57–S62. doi:10.1093/infdis/jiy418.
   PubMedGoogle Scholar